Physician profile
Karen A Chesley
NPI 1063522381
$16,376.53
in general payments reported to CMS, 2019-2025
23 companies · $3,704 in 2025
The $3,704 reported for 2025 was more than what 97% of Psychiatric/Mental Health, Adult (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,527 · 2022: $2,513 · 2023: $3,747 · 2024: $3,886 · 2025: $3,704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,119.18 |
| Education | $217.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,496.98 | 2021-2025 | Caplyta |
| Abbvie INC. | $2,146.33 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,576.28 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $1,369.19 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $1,346.98 | 2022-2025 | Ingrezza |
| Alkermes, INC. | $1,293.40 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Corium, LLC | $1,119.59 | 2022-2024 | Azstarys |
| Vanda Pharmaceuticals INC. | $1,041.25 | 2021-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $850.01 | 2021-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $769.03 | 2021-2025 | Spravato, Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $629.74 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Sunovion Pharmaceuticals INC. | $337.61 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $305.85 | 2023-2024 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $219.94 | 2022-2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $210.12 | 2025 | Jornay Pm |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $183.55 | 2021-2022 | |
| Eisai INC. | $166.08 | 2021 | |
| Axsome Therapeutics, INC. | $106.19 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $95.25 | 2024 | Cobenfy |
| Bausch Health US, LLC | $38.48 | 2022 | |
| Supernus Pharmaceuticals, INC. | $29.67 | 2022 | |
| Jazz Pharmaceuticals INC. | $24.32 | 2021 | |
| Noven Therapeutics, LLC | $20.69 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Chesley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.